Center for Blood Disorders and Stem Cell Transplantation
Center for Blood Disorders and Stem Cell Transplantation
The Swedish Cancer Institute focuses on treating all blood related diseases at the Center for Blood Disorders and Stem Cell Transplantation.
Our team of renowned specialists offers cutting-edge therapies, including novel immunotherapies and stem cell transplantation, while providing access to a wide range of clinical trials. The center is active in the institute's personalized medicine program, using gene sequencing of the patient's unique tumor to understand which treatment would be best for each individual patient.
-
Stem cell pre-collection and mobilization
The first step in the stem cell transplant process is referred to as pre-collection. During this time, patients undergo mobilization. Watch this video for answers to frequently asked questions about the pre-collection process.
-
Stem Cell Collection
After mobilization, a patient’s care team will decide when a patient is ready to begin the next step in the stem cell transplant process, known as collection. Watch this video for answers to frequently asked questions about the collection process.
-
Stem Cell Transplant
The final step of the stem cell transplant is the transplant itself. Stem cells that were previously mobilized and then collected will be returned to the patient’s body. In this video you'll get answers to frequently asked questions about the transplant process.
- CAR-T (chimeric antigen receptor therapy)
- Hematologic malignancies
- Leukemia (acute and chronic)
- Lymphoma (Hodgkin and non-Hodgkin)
- Multiple myeloma
- Myeloproliferative neoplasms
- Anemia
- Clotting disorders
- Cytopenia
- Hemophilia
Print and fax our referral form (PDF). See form for more information.
- Referral phone: 206-991-2040, Option 1
- Referral fax: 206-670-9356
Patients undergoing a stem cell transplant require a personal caregiver to assist them during their treatment and recovery. We've created a resource guide for caregivers while they help during recovery.
Recognition
U.S. News & World Report - High Performing Hospital in Leukemia, Lymphoma, & Myeloma (2024-25)